About Pathway Therapeutics
Pathway Therapeutics is a clinical stage, privately held, pharmaceutical company developing differentiated isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. The company's lead product, PWT33597, is a balanced, dual PI3K alpha/mTOR inhibitor and the first compound with this profile to enter the clinic. Dual inhibition of PI3K and mTOR shuts down the PI3K/mTOR pathway more effectively than single target inhibitors. Of the four PI3K isoforms, PI3K alpha is the key isoform involved in the growth of solid tumors. PI3K alpha is commonly mutated and amplified across a broad range of tumor types and it is also the key isoform involved in signaling downstream of receptor tyrosine kinases. PWT33597 also inhibits both mTOR complexes 1 and 2 (mTORC1 and mTORC2) to turn off a feedback loop that upregulates PI3K when only mTORC1 (target of rapalogs) is inhibited. The profile of PWT33597 supports clinical development in tumors with PI3K alpha pathway dysregulation, (such as breast, endometrial, colorectal cancer, etc.) and mTOR driven tumors (such as renal cell carcinoma, breast, endometrial, sarcoma, and neuroendocrine tumors). Pathway Therapeutics is also developing PI3K delta inhibitors for the treatment of hematological malignancies, and inflammatory and respiratory diseases. PI3K delta inhibition has been clinically validated in hematological malignancies and there is significant preclinical target validation in multiple inflammatory and respiratory diseases. Pathway Therapeutics has identified a potent and selective development candidate, PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. PWT143 has shown superior activity vs. CAL-101 (GS-1101, a compound with clinical proof of concept), in multiple immune cell types and primary leukemia cells. Pathway Therapeutics is also developing additional PI3K delta inhibitors with orthogonal chemistry to PWT143.
Latest Pathway Therapeutics News
Jul 26, 2019
| Source: Research and Markets Dublin, July 26, 2019 (GLOBE NEWSWIRE) -- The "Th17 Inflammatory Pathway Therapeutics Report" report has been added to ResearchAndMarkets.com's offering. Immune-mediated inflammatory diseases (IMIDs) is a term that encompasses a number of common, chronic and complex disorders, characterized by a dysregulation of the normal immune response which leads to inflammation in target organs and, usually, systemic effects as well. Examples include type 1 diabetes (T1D), Crohn's disease (CD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS) and psoriasis. This report examines the therapeutic products and strategies that are being employed to improve outcomes by modulating the intracellular production of inflammatory mediators. What You Will Learn What are the immune factors in the Th17 helper cell pathway that are responsible for immune-mediated inflammatory Autoimmune Diseases? What are the inflammatory-mediated ligands, receptors, signalling proteins and transcription factors that represent druggable targets in the Th17 helper cell? What are the major factors driving the high level of development activity in immune-mediated inflammatory diseases? What is the size of the market today, who are the market share leaders, and what will the market share be in 2022? What are the significant economic, technology, and regulatory factors affecting the market for immune therapeutics Key Topics Covered: Interleukin 6 (IL-6) Interleukin-21 (IL-21) Development-stage Drugs Development-stage Drugs Addressable Market
Pathway Therapeutics Frequently Asked Questions (FAQ)
Where is Pathway Therapeutics's headquarters?
Pathway Therapeutics's headquarters is located at 409 Illinois Street, San Francisco.
What is Pathway Therapeutics's latest funding round?
Pathway Therapeutics's latest funding round is Debt.
How much did Pathway Therapeutics raise?
Pathway Therapeutics raised a total of $24.87M.
Who are the investors of Pathway Therapeutics?
Investors of Pathway Therapeutics include GBS Venture Partners, CM Capital, Breast Cancer Research Trust, Trans Tasman Commercialisation Fund and NZ Growth Capital Partners.